The biopharmaceutical industry is witnessing a paradigm shift with the advent of biologics. As we look forward to the discussions at the 4th Edition of the India Biopharma Leaders Conclave to be held during 13- 14th June 2024 at Le Meriden, Hyderabad, an important topic of discussion will be the emerging trends and technologies in quality assurance for biologics.
Quality assurance plays a pivotal role in the development and manufacturing of biologics. It ensures that these complex medicines meet the highest standards of safety, efficacy, and quality. With the rapid advancements in biotechnology, the quality assurance processes for biologics are also evolving.
One of the key trends in this area is the adoption of real-time process monitoring. With the advancement of analytical technologies, cyber-physical systems, and advanced data interrogation tools, real-time monitoring has become a crucial part of quality control in biologics. It allows for immediate detection and correction of deviations, ensuring consistent product quality.
Another emerging trend is the application of Quality by Design (QbD) approaches in the development of biologics. QbD is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. It requires a holistic understanding of the development process and the deployment of appropriate analytical technologies for real-time monitoring of critical product quality attributes.
Despite these advancements, the industry faces challenges such as maintaining sterility and managing minor deviations that can notably alter the characteristics of the final biologic. Addressing these challenges requires continuous innovation and the adoption of new technologies.
As we anticipate the discussions at the 4th Edition of the India Biopharma Leaders Conclave, the exploration of emerging trends and technologies in quality assurance for biologics will undoubtedly be a key focus. This discussion is expected to shed light on the future of quality assurance in biologics, paving the way for the next wave of biomedical innovation.
– Bala Krishna
